Clinical Trial Update: Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT [Phase 3]

View source ↗

Summary

This update summarizes the efficacy findings from a Phase 3 SPROUT trial evaluating once-daily Symbicort inhaler in children and adolescents with asthma over 12…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED